NCT02459652 is a Phase 2 clinical trial of S-1 in Pancreatic Cancer, sponsored by Japan Adjuvant Study Group of Pancreatic Cancer.

Who is sponsoring NCT02459652?

NCT02459652 is sponsored by Japan Adjuvant Study Group of Pancreatic Cancer.

What drugs are being tested in NCT02459652?

Interventions in NCT02459652: S-1, Radiation Therapy.

What condition does NCT02459652 study?

NCT02459652 studies Pancreatic Cancer.

Is NCT02459652 still recruiting?

NCT02459652 is currently completed. Last updated 27 October 2020.

Last reviewed 2020-10-27 · How we verify

NCT02459652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer

Completed Phase 2 Last updated 27 October 2020

What this trial tests

Phase 2 trial testing S-1 in Pancreatic Cancer in 57 participants. Completed in 17 July 2018.

Timeline

28 December 2012

Primary endpoint
13 May 2016

17 July 2018

Quick facts

Lead sponsor	Japan Adjuvant Study Group of Pancreatic Cancer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	28 December 2012
Primary completion	13 May 2016
Estimated completion	17 July 2018
Sites	22 locations across Japan

Drugs / interventions tested

S-1 — full drug profile →
Radiation Therapy — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Japan Adjuvant Study Group of Pancreatic Cancer

Who can join

Adults 20 to 75, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter Prospective Phase II Study for Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer RATIONALE: Borderline resectable pancreatic cancer is frequently related to a positive surgical margin and has a poor prognosis after resection. Neoadjuvant chemoradiation with intensive local effect may lead to substantial local control and prolongation of survival in borderline resectable pancreatic cancer. PURPOSE: This phase II trial assess efficacy and safety of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of S-1

Trials testing the same drug.

NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07384234 — SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis · Phase 2 · not yet recruiting
NCT07243938 — Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · Phase 2 · not yet recruiting
NCT07018063 — Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02459652 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Japan Adjuvant Study Group of Pancreatic Cancer
Last refreshed: 27 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02459652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing